Drug Delivery Made Simple
Lindy Biosciences has developed highly concentrated suspensions of biologics that enable subcutaneous delivery. The company’s proprietary Microglassification™ technology produces spherical, dense, stable particles of a therapeutic protein. Microglassification™ uses common organic solvents to rapidly (within seconds) and gently remove water from protein solutions.
Microglassification™ gently removes the water from solutions of proteins, or other biologics, resulting in solid, spherical, amorphous microbeads. In this dry state, biologics are stable enough for long-term storage, transport, or incorporation into drug delivery formulations.
Many clinically vital biologics, in particular monoclonal antibodies (mAbs), require higher doses than are currently possible via subcutaneous injection. Dissolving antibody in a volume small enough for subcutaneous delivery results in solutions that are too viscous to inject through a needle, or too unstable to maintain a reasonable shelf-life. By combining the stability of solid mAbs and the beneficial properties of injectable suspensions, we can vastly improve the administration of biotherapeutics.
• High protein concentration
• Stable (formulated as a solid)
• Low viscosity
The video shows one of our early experiments: Microglassification™ of a single protein microdroplet, held on the end of a glass capillary micropipette. The resulting solid microbead consists of pure protein at >1 gram/milliliter. Currently-used methods mimic this experiment, producing protein microdroplets on a bulk scale and dehydrating those microdroplets within seconds.